610 related articles for article (PubMed ID: 27091104)
21. Comprehensive analysis of clinical and biological features in Parkinson's disease associated with the LRRK2 G2019S mutation: Data from the PPMI study.
Sun X; Dou K; Xue L; Xie Y; Yang Y; Xie A
Clin Transl Sci; 2024 Jan; 17(1):e13720. PubMed ID: 38266062
[TBL] [Abstract][Full Text] [Related]
22. Nonmotor symptoms in LRRK2 G2019S associated Parkinson's disease.
Gaig C; Vilas D; Infante J; Sierra M; García-Gorostiaga I; Buongiorno M; Ezquerra M; Martí MJ; Valldeoriola F; Aguilar M; Calopa M; Hernandez-Vara J; Tolosa E
PLoS One; 2014; 9(10):e108982. PubMed ID: 25330404
[TBL] [Abstract][Full Text] [Related]
23. Exhaustion of mitochondrial and autophagic reserve may contribute to the development of LRRK2
Juárez-Flores DL; González-Casacuberta I; Ezquerra M; Bañó M; Carmona-Pontaque F; Catalán-García M; Guitart-Mampel M; Rivero JJ; Tobias E; Milisenda JC; Tolosa E; Marti MJ; Fernández-Santiago R; Cardellach F; Morén C; Garrabou G
J Transl Med; 2018 Jun; 16(1):160. PubMed ID: 29884186
[TBL] [Abstract][Full Text] [Related]
24. Cognitive dysfunction in Tunisian LRRK2 associated Parkinson's disease.
Ben Sassi S; Nabli F; Hentati E; Nahdi H; Trabelsi M; Ben Ayed H; Amouri R; Duda JE; Farrer MJ; Hentati F
Parkinsonism Relat Disord; 2012 Mar; 18(3):243-6. PubMed ID: 22056842
[TBL] [Abstract][Full Text] [Related]
25. Association of Dual LRRK2 G2019S and GBA Variations With Parkinson Disease Progression.
Ortega RA; Wang C; Raymond D; Bryant N; Scherzer CR; Thaler A; Alcalay RN; West AB; Mirelman A; Kuras Y; Marder KS; Giladi N; Ozelius LJ; Bressman SB; Saunders-Pullman R
JAMA Netw Open; 2021 Apr; 4(4):e215845. PubMed ID: 33881531
[TBL] [Abstract][Full Text] [Related]
26. Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations.
Alcalay RN; Levy OA; Waters CC; Fahn S; Ford B; Kuo SH; Mazzoni P; Pauciulo MW; Nichols WC; Gan-Or Z; Rouleau GA; Chung WK; Wolf P; Oliva P; Keutzer J; Marder K; Zhang X
Brain; 2015 Sep; 138(Pt 9):2648-58. PubMed ID: 26117366
[TBL] [Abstract][Full Text] [Related]
27. Olfactory Dysfunction in Parkinson's Disease Patients with the LRRK2 G2385R Variant.
Cao M; Gu ZQ; Li Y; Zhang H; Dan XJ; Cen SS; Li DW; Chan P
Neurosci Bull; 2016 Dec; 32(6):572-576. PubMed ID: 27699718
[TBL] [Abstract][Full Text] [Related]
28. Higher Urine bis(Monoacylglycerol)Phosphate Levels in LRRK2 G2019S Mutation Carriers: Implications for Therapeutic Development.
Alcalay RN; Hsieh F; Tengstrand E; Padmanabhan S; Baptista M; Kehoe C; Narayan S; Boehme AK; Merchant K
Mov Disord; 2020 Jan; 35(1):134-141. PubMed ID: 31505072
[TBL] [Abstract][Full Text] [Related]
29. The LRRK2 G2019S mutation in a series of Argentinean patients with Parkinson's disease: clinical and demographic characteristics.
Gatto EM; Parisi V; Converso DP; Poderoso JJ; Carreras MC; Martí-Massó JF; Paisán-Ruiz C
Neurosci Lett; 2013 Mar; 537():1-5. PubMed ID: 23340200
[TBL] [Abstract][Full Text] [Related]
30. Greater improvement in LRRK2 G2019S patients undergoing Subthalamic Nucleus Deep Brain Stimulation compared to non-mutation carriers.
Sayad M; Zouambia M; Chaouch M; Ferrat F; Nebbal M; Bendini M; Lesage S; Brice A; Brahim Errahmani M; Asselah B
BMC Neurosci; 2016 Feb; 17():6. PubMed ID: 26831335
[TBL] [Abstract][Full Text] [Related]
31. Application of the Movement Disorder Society prodromal criteria in healthy G2019S-LRRK2 carriers.
Mirelman A; Saunders-Pullman R; Alcalay RN; Shustak S; Thaler A; Gurevich T; Raymond D; Mejia-Santana H; Orbe Reilly M; Ozelius L; Clark L; Gana-Weisz M; Bar-Shira A; Orr-Utreger A; Bressman SB; Marder K; Giladi N;
Mov Disord; 2018 Jul; 33(6):966-973. PubMed ID: 29603409
[TBL] [Abstract][Full Text] [Related]
32. The Effect of p.G2019S Mutation in the
Usenko TS; Timofeeva A; Beletskaia M; Basharova K; Baydakova G; Bezrukova A; Grunina M; Emelyanov A; Miliukhina I; Zakharova E; Pchelina S
J Integr Neurosci; 2024 Jan; 23(1):16. PubMed ID: 38287861
[TBL] [Abstract][Full Text] [Related]
33. Prospective clinical and DaT-SPECT imaging in premotor
Sierra M; Martínez-Rodríguez I; Sánchez-Juan P; González-Aramburu I; Jiménez-Alonso M; Sánchez-Rodríguez A; Berciano J; Banzo I; Infante J
Neurology; 2017 Aug; 89(5):439-444. PubMed ID: 28679601
[TBL] [Abstract][Full Text] [Related]
34. Arm swing as a potential new prodromal marker of Parkinson's disease.
Mirelman A; Bernad-Elazari H; Thaler A; Giladi-Yacobi E; Gurevich T; Gana-Weisz M; Saunders-Pullman R; Raymond D; Doan N; Bressman SB; Marder KS; Alcalay RN; Rao AK; Berg D; Brockmann K; Aasly J; Waro BJ; Tolosa E; Vilas D; Pont-Sunyer C; Orr-Urtreger A; Hausdorff JM; Giladi N
Mov Disord; 2016 Oct; 31(10):1527-1534. PubMed ID: 27430880
[TBL] [Abstract][Full Text] [Related]
35. [Clinical features of LRRK2-associated Parkinson's disease].
Pchelina SN; Ivanova ON; Emel'ianov AK; Iakimovskiĭ AF
Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(12):56-62. PubMed ID: 22433811
[TBL] [Abstract][Full Text] [Related]
36. Connectivity of corticostriatal circuits in nonmanifesting LRRK2 G2385R and R1628P carriers.
Zhang D; Yao J; Ma J; Gao L; Sun J; Fang J; He H; Wu T
CNS Neurosci Ther; 2022 Dec; 28(12):2024-2031. PubMed ID: 35934920
[TBL] [Abstract][Full Text] [Related]
37. Clinical Heterogeneity Among
Shu L; Zhang Y; Pan H; Xu Q; Guo J; Tang B; Sun Q
Front Aging Neurosci; 2018; 10():283. PubMed ID: 30283330
[No Abstract] [Full Text] [Related]
38. Olfactory dysfunction in LRRK2 G2019S mutation carriers.
Saunders-Pullman R; Stanley K; Wang C; San Luciano M; Shanker V; Hunt A; Severt L; Raymond D; Ozelius LJ; Lipton RB; Bressman SB
Neurology; 2011 Jul; 77(4):319-24. PubMed ID: 21753159
[TBL] [Abstract][Full Text] [Related]
39. Higher frequency of certain cancers in LRRK2 G2019S mutation carriers with Parkinson disease: a pooled analysis.
Agalliu I; San Luciano M; Mirelman A; Giladi N; Waro B; Aasly J; Inzelberg R; Hassin-Baer S; Friedman E; Ruiz-Martinez J; Marti-Masso JF; Orr-Urtreger A; Bressman S; Saunders-Pullman R
JAMA Neurol; 2015 Jan; 72(1):58-65. PubMed ID: 25401981
[TBL] [Abstract][Full Text] [Related]
40. Serum Uric Acid in LRRK2 Related Parkinson's Disease: Longitudinal Data from the PPMI Study.
Bougea A; Koros C; Papagiannakis N; Simitsi AM; Prentakis A; Papadimitriou D; Pachi I; Antonelou R; Angelopoulou E; Beratis I; Bozi M; Papageorgiou SG; Trapali XG; Stamelou M; Stefanis L
J Parkinsons Dis; 2021; 11(2):633-640. PubMed ID: 33682725
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
